Needlestick Prevention Claims Require Support Of Clinical Data, Panel Says
This article was originally published in The Gray Sheet
Executive Summary
Clinical data demonstrating efficacy of a sharps injury prevention device should be submitted to FDA in support of any claim, suggestion, or hint that the device reduces the incidence of sharps injury, FDA's General Hospital and Personal Use Devises Advisory Panel concluded.